Scholarlink

Background <p>Ovarian cancer (OC) remains one of the leading causes of gynecological cancer-related mortality, with limited biomarkers for early detection and prognosis. Changes in DNA methylation—stable and detectable in blood—are potential candidates for clinical application. In our earlier genome-wide methylation study involving monozygotic twins where one had ovarian cancer and the other did not, we identified two genes, <i>RBBP7</i> and <i>RIBC1</i>, as differentially methylated. These findings laid the groundwork for further targeted investigation.</p> Methods and Results <p>Peripheral blood methylation of <i>RBBP7</i> and <i>RIBC1</i> was evaluated in 387 ovarian cancer patients, 50 benign ovarian disease patients, and 100 healthy controls using a bisulfite-free, methylation-sensitive restriction enzyme (MSRE)-based qPCR assay. In this approach, DNA is divided into digested and undigested reactions, and methylation levels are calculated from Ct differences. Methylation levels differed across groups, with <i>RBBP7</i> showing a clearer discriminatory pattern (<i>p</i> &lt; 0.001) and associations with disease severity (<i>p</i> &lt; 0.001) and CA125 levels (<i>p</i> = 0.05). RIBC1 also differed between ovarian cancer and healthy controls (<i>p</i> &lt; 0.001) but showed no significant associations with clinicopathological parameters.</p> Conclusion <p><i>RBBP7</i> methylation appears to be a potential candidate biomarker associated with disease characteristics and progression patterns of ovarian cancer. These findings suggest that <i>RBBP7</i> methylation may have potential for integration into future multi-marker diagnostic and risk-stratification approaches, pending further validation. While <i>RIBC1</i> methylation also showed differential patterns, its clinical relevance appears limited and requires further investigation. These findings support the integration of <i>RBBP7</i> methylation assessment into early-stage diagnostic workflows and risk-stratification strategies for ovarian cancer, enabling more precise clinical decision-making. Future multicenter prospective studies are warranted before clinical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer

  • 期刊论文

  • 发表日期：

    2026年7月29日

查看全文
  • Özge Şükrüoğlu Erdoğan,
  • Seda Kılıç Erciyas,
  • Betül Çelik Demirbaş,
  • Ahmet Dinç,
  • Elif Ünal,
  • Funda Güngör Uğurlucan,
  • Demet Akdeniz Ödemiş,
  • Özge Pasin,
  • Pınar Mualla Saip,
  • Hülya Yazıcı,
  • Seref Bugra Tuncer

摘要

Background

Ovarian cancer (OC) remains one of the leading causes of gynecological cancer-related mortality, with limited biomarkers for early detection and prognosis. Changes in DNA methylation—stable and detectable in blood—are potential candidates for clinical application. In our earlier genome-wide methylation study involving monozygotic twins where one had ovarian cancer and the other did not, we identified two genes, RBBP7 and RIBC1, as differentially methylated. These findings laid the groundwork for further targeted investigation.

Methods and Results

Peripheral blood methylation of RBBP7 and RIBC1 was evaluated in 387 ovarian cancer patients, 50 benign ovarian disease patients, and 100 healthy controls using a bisulfite-free, methylation-sensitive restriction enzyme (MSRE)-based qPCR assay. In this approach, DNA is divided into digested and undigested reactions, and methylation levels are calculated from Ct differences. Methylation levels differed across groups, with RBBP7 showing a clearer discriminatory pattern (p < 0.001) and associations with disease severity (p < 0.001) and CA125 levels (p = 0.05). RIBC1 also differed between ovarian cancer and healthy controls (p < 0.001) but showed no significant associations with clinicopathological parameters.

Conclusion

RBBP7 methylation appears to be a potential candidate biomarker associated with disease characteristics and progression patterns of ovarian cancer. These findings suggest that RBBP7 methylation may have potential for integration into future multi-marker diagnostic and risk-stratification approaches, pending further validation. While RIBC1 methylation also showed differential patterns, its clinical relevance appears limited and requires further investigation. These findings support the integration of RBBP7 methylation assessment into early-stage diagnostic workflows and risk-stratification strategies for ovarian cancer, enabling more precise clinical decision-making. Future multicenter prospective studies are warranted before clinical implementation.